Brokers Set Expectations for TEVA Q3 Earnings

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) – HC Wainwright issued their Q3 2026 EPS estimates for Teva Pharmaceutical Industries in a research report issued on Monday, November 2nd. HC Wainwright analyst D. Tsao anticipates that the company will post earnings of $0.71 per share for the quarter. HC Wainwright has a “Buy” rating and a $52.00 price target on the stock. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.00 per share. HC Wainwright also issued estimates for Teva Pharmaceutical Industries’ Q4 2026 earnings at $0.75 EPS, FY2026 earnings at $1.94 EPS, Q1 2027 earnings at $0.62 EPS, Q2 2027 earnings at $0.72 EPS, Q3 2027 earnings at $0.82 EPS, Q4 2027 earnings at $0.87 EPS and FY2027 earnings at $3.03 EPS.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Tuesday, November 3rd. The company reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.14. The company had revenue of $4.39 billion for the quarter, compared to analyst estimates of $4.23 billion. Teva Pharmaceutical Industries had a net margin of 2.94% and a return on equity of 33.22%. The business’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period last year, the business posted $0.78 earnings per share.

TEVA has been the topic of several other reports. JPMorgan Chase & Co. lifted their target price on Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the stock an “overweight” rating in a report on Monday, October 12th. UBS Group increased their price target on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a “buy” rating in a report on Friday, September 4th. Wall Street Zen lowered Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Leerink Partners began coverage on Teva Pharmaceutical Industries in a report on Wednesday, September 9th. They set an “outperform” rating and a $45.00 price objective on the stock. Finally, Barclays boosted their price objective on Teva Pharmaceutical Industries from $42.00 to $47.00 and gave the company an “overweight” rating in a research report on Thursday, October 15th. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $46.69.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA stock opened at $41.83 on Thursday. The company has a quick ratio of 0.67, a current ratio of 0.88 and a debt-to-equity ratio of 1.56. Teva Pharmaceutical Industries has a 12-month low of $22.70 and a 12-month high of $43.34. The firm has a fifty day moving average of $39.32 and a 200-day moving average of $34.68. The firm has a market capitalization of $48.74 billion, a price-to-earnings ratio of 97.27, a price-to-earnings-growth ratio of 3.89 and a beta of 0.97.

Insider Transactions at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 367,600 shares of the stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $39.06, for a total transaction of $14,358,456.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Brian Savage sold 7,342 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $38.85, for a total value of $285,236.70. Following the completion of the sale, the insider directly owned 8,500 shares in the company, valued at approximately $330,225. This represents a 46.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.54% of the company’s stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several institutional investors have recently bought and sold shares of TEVA. Parallel Advisors LLC grew its holdings in shares of Teva Pharmaceutical Industries by 8.7% in the 3rd quarter. Parallel Advisors LLC now owns 4,626 shares of the company’s stock valued at $183,000 after acquiring an additional 370 shares in the last quarter. Sage Rhino Capital LLC increased its position in shares of Teva Pharmaceutical Industries by 5.6% in the first quarter. Sage Rhino Capital LLC now owns 7,874 shares of the company’s stock valued at $237,000 after acquiring an additional 417 shares during the last quarter. Envestnet Portfolio Solutions Inc. raised its holdings in Teva Pharmaceutical Industries by 7.1% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 7,311 shares of the company’s stock worth $248,000 after acquiring an additional 483 shares in the last quarter. First Trust Advisors LP raised its holdings in Teva Pharmaceutical Industries by 5.9% during the first quarter. First Trust Advisors LP now owns 9,619 shares of the company’s stock worth $290,000 after acquiring an additional 539 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its position in Teva Pharmaceutical Industries by 64.0% during the first quarter. EverSource Wealth Advisors LLC now owns 1,658 shares of the company’s stock valued at $50,000 after purchasing an additional 647 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Key Headlines Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Earnings and guidance beat expectations: Third-quarter adjusted earnings were $0.86 per share versus $0.72 expected, and revenue of about $4.39 billion topped the $4.23 billion consensus. Teva raised its 2026 revenue and product-sales outlook, citing growth in branded medicines. Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock Up
• Positive Sentiment: UZEDY sales surged: The long-acting schizophrenia treatment generated $85 million in U.S. third-quarter sales, up 96% year over year. Teva lifted its 2026 UZEDY revenue forecast to $290 million–$310 million from $270 million–$290 million. UZEDY Q3 U.S. Net Sales Reach $85M
• Positive Sentiment: Analyst endorsement: TD Cowen raised its price target from $55 to $57 and maintained a Buy rating, signaling confidence in further potential upside. TD Cowen price-target update
• Positive Sentiment: Biosimilar portfolio expansion: Teva secured U.S. commercialization rights to two Samsung Bioepis immunology biosimilars, broadening its product portfolio and potential future revenue sources. Teva and Samsung Bioepis biosimilar agreement
• Negative Sentiment: Drug-development setback and sales pressure: Teva ended its Phase 2 emrusolmin study after an interim review found insufficient efficacy. Quarterly revenue also declined 1.9% year over year, and the company expects U.S. drug-pricing pressure to affect Austedo. Why Teva Is Dropping a Drug Trial While Raising Its Outlook

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company is one of the world’s largest producers of generic medicines and develops, manufactures and distributes prescription products across a broad range of therapeutic areas.

Teva’s portfolio includes generic medicines, specialty pharmaceuticals, biosimilars, active pharmaceutical ingredients and over-the-counter products. Its specialty medicines include treatments for neurological and movement disorders, respiratory conditions, migraine and other chronic diseases.